Blog

Canada Goose (GOOS) ended the recent trading session at $9.81, demonstrating a -1.21% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of

In the latest close session, Intuit (INTU) was down 1.27% at $291.06. This move lagged the S&P 500's daily loss of 1.01%. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.4%.

Marathon Digital Holdings, Inc. (MARA) closed the most recent trading day at $10.69, moving -6.39% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of

Salesforce (CRM) closed at $170.77 in the latest trading session, marking a -1.11% move from the prior day. This change lagged the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing

CleanSpark (CLSK) closed at $13.03 in the latest trading session, marking a +1.01% move from the prior day. The stock's change was more than the S&P 500's daily loss of 1.01%. At the same time, the

Cava Group (CAVA) ended the recent trading session at $68.85, demonstrating a +1.1% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 1.01%. On the other

Abercrombie & Fitch (ANF) ended the recent trading session at $95.24, demonstrating a -2.19% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a

In the latest close session, Alibaba (BABA) was down 2.14% at $114.97. The stock's performance was behind the S&P 500's daily loss of 1.01%. Meanwhile, the Dow experienced a drop of 0.77%, and the

In the latest close session, Lowe's (LOW) was down 3.44% at $208.73. The stock trailed the S&P 500, which registered a daily loss of 1.01%. Meanwhile, the Dow experienced a drop of 0.77%, and the

The 2026 Q2 earnings season is in full swing following the release of the big banks’ results, with many other notable companies on deck in the coming days and weeks.

Concerning next week’s docket

Friday, July 17, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc.

Despite recent volatility, stocks have been on a tear this year.YTD, through Friday, 7/17, the Dow is up 8.85%, the S&P 500 is up 9.55%, and the tech-heavy Nasdaq is up 12.8%. Additionally, the

Despite recent volatility, stocks have been on a tear this year.YTD, through Friday, 7/17, the Dow is up 8.85%, the S&P 500 is up 9.55%, and the tech-heavy Nasdaq is up 12.8%. Additionally, the

The sharp pullback in D-Wave Quantum QBTS this month has shifted investor attention from the quantum computing sector's long-term promise to its near-term execution risks. After delivering

Micron Technology, Inc. MU and Taiwan Semiconductor Manufacturing Company Limited TSM, better known as TSMC, have both benefited from the artificial intelligence (AI) boom and have delivered

uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare

Realty Income O is widening its growth playbook beyond buying properties with its balance sheet. The net-lease giant is building partnerships that bring in outside capital, open new sectors and

uniQure N.V. QURE has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease.

The question is whether the move already reflects too much optimism

AT&T Inc. T is scheduled to report second-quarter 2026 earnings on July 22, before the opening bell. The Zacks Consensus Estimate for revenues and earnings is pegged at $32.04 billion and 59 cents

uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington’s disease, an area where disease-modifying options

Harmony Biosciences HRMY announced preliminary second-quarter 2026 results.

The company registered a record $261 million in net product revenues from its lead drug, Wakix (pitolisant).

Wakix

Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at

Honeywell Aerospace HONA has entered the market with exposure to several aerospace growth channels, from commercial aviation to defense and space. The stock’s long-term case depends on whether those

Doximity DOCS is entering a pivotal phase as it accelerates investments in artificial intelligence to expand beyond its core physician engagement platform. While robust physician adoption, growing

Honeywell Aerospace Inc. HONA enters the public market with scale, aerospace focus and a valuation that invites debate. The stock trades like a newly separated supplier with strong end-market